Therapeutic antibodies: successes, limitations and hopes for the future

2009/04/28 by Patrick Chames, Marc Van Regenmortel, Etienne Weiss +2 · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Monoclonal and Polyclonal Antibodies Research #Protein purification and stability #T-cell and B-cell Immunology

paper · pdf · doi:10.1111/j.1476-5381.2009.00190.x

Abstract

With more than 20 molecules in clinical use, monoclonal antibodies have finally come of age as therapeutics, generating a market value of 11 billion in 2004, expected to reach 26 billion by 2010. While delivering interesting results in the treatment of several major diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation, clinical trials and research are generating a wealth of useful information, for instance about associations of clinical responses with Fc receptor polymorphisms and the infiltration and recruitment of effector cells into targeted tissues. Some functional limitations of therapeutic antibodies have come to light such as inadequate pharmacokinetics and tissue accessibility as well as impaired interactions with the immune system, and these deficiencies point to areas where additional research is needed. This review aims at giving an overview of the current state of the art and describes the most promising avenues that are being followed to create the next generation of antibody‐based therapeutic agents. This article is part of a themed section on Vector Design and Drug Delivery. For a list of all articles in this section see the end of this paper, or visit: http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009

Cited by

• Peptide design to control protein–protein interactions
• Advancing Antibody Engineering through Synthetic Evolution and Machine Learning
• The evolution of commercial drug delivery technologies
• Bispecific antibodies for cancer therapy: the light at the end of the tunnel? [europepmc]
• Analysis on the current status of targeted drug delivery to tumors. [europepmc]
• Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. [europepmc]
• Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. [europepmc]
• Identification and characterization of host cell protein product-associated impurities in monoclonal antibody bioprocessing. [europepmc]
• An overview of clinical and commercial impact of drug delivery systems. [europepmc]
• Insulin-like growth factor system in cancer: novel targeted therapies. [europepmc]
• Human plasma protein N-glycosylation. [europepmc]
• Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells. [europepmc]
• Determination of half-maximal inhibitory concentration using biosensor-based protein interaction analysis. [europepmc]
• MERS-CoV spike protein: a key target for antivirals. [europepmc]
• Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. [europepmc]
• Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). [europepmc]
• Functional muscle recovery with nanoparticle-directed M2 macrophage polarization in mice. [europepmc]
• How mRNA therapeutics are entering the monoclonal antibody field. [europepmc]
• Progress on Modulating Tumor-Associated Macrophages with Biomaterials. [europepmc]
• AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. [europepmc]
• Antibody Structure and Function: The Basis for Engineering Therapeutics. [europepmc]
• Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. [europepmc]
• Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. [europepmc]
• Herpes Simplex Virus Cell Entry Mechanisms: An Update. [europepmc]
• Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs. [europepmc]
• Emerging new therapeutic antibody derivatives for cancer treatment. [europepmc]
• Virus-like particle vaccinology, from bench to bedside. [europepmc]
• Exploring treatment options in cancer: Tumor treatment strategies. [europepmc]

Related

• Structure and function of therapeutic antibodies approved by the US FDA in 2023
• Structure and function of therapeutic antibodies approved by the US FDA in 2024
• Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design
• Concise Review: Stem Cells As an Emerging Platform for Antibody Therapy of Cancer
• Antibody–drug conjugates in cancer and beyond: progress, promise, and perspectives